We are live on
!
Find out more
WT
Wellcome Trust Portfolio holdings
AUM
$9.01B
1-Year Est. Return
12.05%
This Fund
S&P 500
This Quarter
Est. Return
+5.3%
1 Year Est. Return
+12.05%
3 Year Est. Return
+59.66%
5 Year Est. Return
+58.12%
10 Year Est. Return
+403.84%
AUM
$8.28B
AUM Growth
+$63.8M
(+0.78%)
Cap. Flow
-$272M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
65.93%
Holding
22
New
–
Increased
1
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maplebear
CART
|
+$145M |
| 2 |
ServiceNow
NOW
|
+$76M |
| 3 |
Amazon
AMZN
|
+$51.1M |
| 4 |
Samsara
IOT
|
+$21.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.61% |
| 2 | Financials | 18.45% |
| 3 | Consumer Discretionary | 17.57% |
| 4 | Healthcare | 11.78% |
| 5 | Communication Services | 8.26% |
Similar funds
A
VAS
AI
AI
HI
SFM
MIH
RWP
Wellcome Trust's Q4 2024 Portfolio in Review
As of Q4 2024, Wellcome Trust held 22 positions worth $8.28B, up 0.78% from $8.21B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Wellcome Trust withdrew a net $272M in Q4 2024, closing 1 position and reducing 3 holdings. Its most notable exit was Maplebear, an estimated $145M position sold in full.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 35% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Wellcome Trust added an estimated $21M to Edwards Lifesciences.
- Wellcome Trust added most to Edwards Lifesciences in Q4 2024, an estimated $21M increase.
- Wellcome Trust's biggest Q4 2024 reduction was ServiceNow, cutting an estimated $76M.
- Wellcome Trust fully exited Maplebear in Q4 2024, selling an estimated $145M.
- Wellcome Trust's ten largest holdings make up 66% of its $8.28B portfolio in Q4 2024.
- Wellcome Trust opened 0 new positions and closed 1 in Q4 2024.
- Wellcome Trust's portfolio value rose 0.78% quarter-over-quarter to $8.28B.
Based on Wellcome Trust's 13F filing for Q4 2024, filed 13 Jan 2025.